Teleflex (NYSE:TFX – Get Rating) had its target price dropped by investment analysts at Truist Financial from $265.00 to $241.00 in a report released on Thursday, The Fly reports. Truist Financial's price target points to a potential upside of 12.52% from the stock's current price.
A number of other brokerages have also commented on TFX. Piper Sandler reduced their target price on shares of Teleflex from $295.00 to $265.00 in a research report on Thursday, July 28th. Wolfe Research assumed coverage on shares of Teleflex in a research report on Tuesday, July 5th. They set an "outperform" rating and a $300.00 target price on the stock. Wells Fargo & Company lowered shares of Teleflex from an "overweight" rating to an "equal weight" rating and set a $248.00 target price on the stock. in a research report on Friday, July 29th. Morgan Stanley dropped their price objective on shares of Teleflex from $300.00 to $278.00 and set an "equal weight" rating on the stock in a research note on Friday, July 29th. Finally, StockNews.com downgraded shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $322.70.
Get
Teleflex alerts:
Teleflex Trading Down 2.7 %
Shares of Teleflex stock opened at $214.19 on Thursday. The company has a market capitalization of $10.05 billion, a P/E ratio of 19.91, a P/E/G ratio of 2.17 and a beta of 1.10. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.43 and a current ratio of 2.27. The company has a fifty day moving average of $242.25 and a 200 day moving average of $279.20. Teleflex has a fifty-two week low of $213.76 and a fifty-two week high of $391.39.
Teleflex (NYSE:TFX – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical technology company reported $3.39 EPS for the quarter, beating the consensus estimate of $3.34 by $0.05. Teleflex had a net
margin of 18.16% and a return on equity of 16.84%. The business had revenue of $704.50 million during the quarter, compared to the consensus estimate of $719.50 million. During the same quarter in the prior year, the firm earned $3.35 EPS. The business's revenue was down 1.3% on a year-over-year basis. On average, sell-side analysts anticipate that Teleflex will post 13.13 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TFX. Inspire Investing LLC purchased a new stake in shares of Teleflex during the first quarter worth about $368,000. National Bank of Canada FI boosted its position in Teleflex by 7,726.3% during the first quarter. National Bank of Canada FI now owns 13,383 shares of the medical technology company's stock worth $4,633,000 after acquiring an additional 13,212 shares during the last quarter. Regentatlantic Capital LLC boosted its position in Teleflex by 2.3% during the first quarter. Regentatlantic Capital LLC now owns 2,215 shares of the medical technology company's stock worth $786,000 after acquiring an additional 50 shares during the last quarter. Procyon Advisors LLC boosted its position in Teleflex by 47.0% during the second quarter. Procyon Advisors LLC now owns 992 shares of the medical technology company's stock worth $244,000 after acquiring an additional 317 shares during the last quarter. Finally, Stanley Laman Group Ltd. boosted its position in Teleflex by 16.7% during the first quarter. Stanley Laman Group Ltd. now owns 8,940 shares of the medical technology company's stock worth $3,172,000 after acquiring an additional 1,282 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company's stock.
About Teleflex
(Get Rating)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Further Reading
- Get a free copy of the StockNews.com research report on Teleflex (TFX)
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
